Compare Nasdaq Inc (NDAQ) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs GeneDx Holdings Corp — how do they compare? Nasdaq Inc trades at $93.65 (market cap $51.63B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Nasdaq Inc is far larger — about 25.6× GeneDx Holdings Corp's market cap, and Nasdaq Inc pays a 1.26% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq Inc for 126 Days and GeneDx Holdings Corp for 19 Days on average.
| NDAQ | WGS | |
|---|---|---|
Market Cap | $51.63B | $2.02B |
Volume | 2,668,175 | 734,640 |
Sector | Financials | Health |
52-Week High | $100.98 | $167.51 |
52-Week Low | $76.85 | $34.51 |
Typical Hold Time | 126 Days | 19 Days |
Enterprise Value | $58.09B | $2.05B |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nasdaq Inc. (NDAQ) trades at $93.65, up 1.87% on the day, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting further upside, while recent earnings beats and a 22.52% net income margin highlight robust profitability. Positive news includes the addition of Moderna to the Nasdaq-100 Index and HSBC adopting Nasdaq's Calypso platform, signaling business growth.
Outlook remains favorable with a consensus price target of $110.43, implying 18% upside. Key risks include cash flow volatility and high debt levels, but analyst sentiment is strongly bullish with 61% buy ratings. Revenue growth and AI-driven platform adoption present opportunities, though market volatility and competitive pressures warrant monitoring.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
